Literature DB >> 15297610

Autocatalytic self-propagation of misfolded prion protein.

Jan Bieschke1, Petra Weber, Nikolaus Sarafoff, Michael Beekes, Armin Giese, Hans Kretzschmar.   

Abstract

Prions are thought to replicate in an autocatalytic process that converts cellular prion protein (PrP(C)) to the disease-associated misfolded PrP isoform (PrP(Sc)). Our study scrutinizes this hypothesis by in vitro protein misfolding cyclic amplification (PMCA). In serial transmission PMCA experiments, PrP(Sc) was inoculated into healthy hamster brain homogenate containing PrP(C). Misfolded PrP was amplified by rounds of sonication and incubation and reinoculated into fresh brain homogenate every 10 PMCA rounds. The amplification depended on PrP(C) substrate and could be inhibited by recombinant hamster PrP. In serial dilution experiments, newly formed misfolded and proteinase K-resistant PrP (PrPres) catalyzed the structural conversion of PrP(C) as efficiently as PrP(Sc) from brain of scrapie (263K)-infected hamsters, yielding an approximately 300-fold total amplification of PrPres after 100 rounds, which confirms an autocatalytic PrP-misfolding cascade as postulated by the prion hypothesis. PrPres formation was not paralleled by replication of biological infectivity, which appears to require factors additional to PrP-misfolding autocatalysis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297610      PMCID: PMC514458          DOI: 10.1073/pnas.0404650101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding.

Authors:  G P Saborio; B Permanne; C Soto
Journal:  Nature       Date:  2001-06-14       Impact factor: 49.962

2.  RNA molecules stimulate prion protein conversion.

Authors:  Nathan R Deleault; Ralf W Lucassen; Surachai Supattapone
Journal:  Nature       Date:  2003-10-16       Impact factor: 49.962

3.  Molecular basis of scrapie strain glycoform variation.

Authors:  Ina Vorberg; Suzette A Priola
Journal:  J Biol Chem       Date:  2002-07-23       Impact factor: 5.157

4.  In vitro amplification of protease-resistant prion protein requires free sulfhydryl groups.

Authors:  Ralf Lucassen; Koren Nishina; Surachai Supattapone
Journal:  Biochemistry       Date:  2003-04-15       Impact factor: 3.162

5.  Prion rods contain an inert polysaccharide scaffold.

Authors:  T R Appel; C Dumpitak; U Matthiesen; D Riesner
Journal:  Biol Chem       Date:  1999-11       Impact factor: 3.915

6.  Pathogenesis of scrapie (strain 263K) in hamsters infected intracerebrally, intraperitoneally or intraocularly.

Authors:  R H Kimberlin; C A Walker
Journal:  J Gen Virol       Date:  1986-02       Impact factor: 3.891

7.  The synthesis of a self-propagating and infectious nucleic acid with a purified enzyme.

Authors:  S Spiegelman; I Haruna; I B Holland; G Beaudreau; D Mills
Journal:  Proc Natl Acad Sci U S A       Date:  1965-09       Impact factor: 11.205

8.  Purified prion proteins and scrapie infectivity copartition into liposomes.

Authors:  R Gabizon; M P McKinley; S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

9.  Characteristics of a short incubation model of scrapie in the golden hamster.

Authors:  R H Kimberlin; C Walker
Journal:  J Gen Virol       Date:  1977-02       Impact factor: 3.891

10.  Novel proteinaceous infectious particles cause scrapie.

Authors:  S B Prusiner
Journal:  Science       Date:  1982-04-09       Impact factor: 47.728

View more
  36 in total

1.  Agent strain variation in human prion disease: insights from a molecular and pathological review of the National Institutes of Health series of experimentally transmitted disease.

Authors:  Piero Parchi; Maura Cescatti; Silvio Notari; Walter J Schulz-Schaeffer; Sabina Capellari; Armin Giese; Wen-Quan Zou; Hans Kretzschmar; Bernardino Ghetti; Paul Brown
Journal:  Brain       Date:  2010-09-07       Impact factor: 13.501

Review 2.  Redox control of prion and disease pathogenesis.

Authors:  Neena Singh; Ajay Singh; Dola Das; Maradumane L Mohan
Journal:  Antioxid Redox Signal       Date:  2010-06-01       Impact factor: 8.401

3.  Selective amplification of classical and atypical prions using modified protein misfolding cyclic amplification.

Authors:  Natallia Makarava; Regina Savtchenko; Ilia V Baskakov
Journal:  J Biol Chem       Date:  2012-11-20       Impact factor: 5.157

4.  Prions Strongly Reduce NMDA Receptor S-Nitrosylation Levels at Pre-symptomatic and Terminal Stages of Prion Diseases.

Authors:  Elisa Meneghetti; Lisa Gasperini; Tommaso Virgilio; Fabio Moda; Fabrizio Tagliavini; Federico Benetti; Giuseppe Legname
Journal:  Mol Neurobiol       Date:  2019-02-01       Impact factor: 5.590

5.  Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.

Authors:  Alexander Pfeifer; Sabina Eigenbrod; Saba Al-Khadra; Andreas Hofmann; Gerda Mitteregger; Markus Moser; Uwe Bertsch; Hans Kretzschmar
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

Review 6.  The genetic epidemiology of neurodegenerative disease.

Authors:  Lars Bertram; Rudolph E Tanzi
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

Review 7.  Chaperones and proteases: cellular fold-controlling factors of proteins in neurodegenerative diseases and aging.

Authors:  Marie-Pierre Hinault; Anat Ben-Zvi; Pierre Goloubinoff
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

8.  Amyloid-β(1-42) Aggregation Initiates Its Cellular Uptake and Cytotoxicity.

Authors:  Sha Jin; Niraja Kedia; Eva Illes-Toth; Ivan Haralampiev; Simon Prisner; Andreas Herrmann; Erich E Wanker; Jan Bieschke
Journal:  J Biol Chem       Date:  2016-07-25       Impact factor: 5.157

Review 9.  Natural compounds may open new routes to treatment of amyloid diseases.

Authors:  Jan Bieschke
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

10.  Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease.

Authors:  Jens Wagner; Sergey Ryazanov; Andrei Leonov; Johannes Levin; Song Shi; Felix Schmidt; Catharina Prix; Francisco Pan-Montojo; Uwe Bertsch; Gerda Mitteregger-Kretzschmar; Markus Geissen; Martin Eiden; Fabienne Leidel; Thomas Hirschberger; Andreas A Deeg; Julian J Krauth; Wolfgang Zinth; Paul Tavan; Jens Pilger; Markus Zweckstetter; Tobias Frank; Mathias Bähr; Jochen H Weishaupt; Manfred Uhr; Henning Urlaub; Ulrike Teichmann; Matthias Samwer; Kai Bötzel; Martin Groschup; Hans Kretzschmar; Christian Griesinger; Armin Giese
Journal:  Acta Neuropathol       Date:  2013-04-19       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.